Citius Pharmaceuticals, Inc. (CTXR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+64.2%

$0.92

vs $0.56 price

Levered DCF

$0.22

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-4.03

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.37×	-2.1×	-3.07×	-5.26×	-9×	-2.32×	-24.6×	-35.68×
P/B	0.2×	2.07×	1.14×	1.72×	1.67×	1.21×	1.04×	1.07×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.3×	-3.68×	-2.12×	-4.1×	-6.47×	-1.61×	-1.14×	-1.51×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.62×	0.4×	5.95×	9.84×	18.28×	3.41×	1.72×	3.16×
Debt / equity	0.03×	0×	0.01×	0.01×	0.01×	0.04×	0.01×	0.01×
Interest coverage	-143.87×	0×	0×	0×	-2,171.04×	-1,130.01×	-948.63×	-870.64×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-55.4%	-55.9%	-35.8%	-32.7%	-17.4%	-52.1%	-63.9%	-45.0%
Return on invested capital	-44.2%	-51.8%	-37.5%	-30.4%	-17.0%	-44.3%	-63.5%	-49.2%
Return on assets	-28.6%	-33.6%	-31.4%	-29.5%	-16.2%	-40.1%	-53.7%	-40.4%
Free cash flow yield	-193.5%	-19.4%	-28.1%	-16.0%	-29.1%	-41.6%	-48.9%	-37.9%
Earnings yield	-272.8%	-27.0%	-31.4%	-19.0%	-10.5%	-43.1%	-61.2%	-42.0%
Enterprise value	$11.3M	$142.1M	$77.5M	$135.7M	$151.2M	$28.2M	$17.7M	$20.9M
Net debt / EBITDA	0.06×	0.08×	0.71×	1.24×	2.96×	0.71×	0.5×	0.65×
Cash conversion cycle (days)	14,639	5,819	0	0	-2,827	-4,447	-1,109,119	-327,614